Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines

Background To improve cancer therapy, it is critical to target metastasizing cells. Circulating tumor cells (CTCs) are rare cells found in the blood of patients with solid tumors and may play a key role in cancer dissemination. Uncovering CTC phenotypes offers a potential avenue to inform treatment. However, CTC transcriptional profiling is limited by leukocyte contamination; an approach to surmount this problem is single cell analysis. Here we demonstrate feasibility of performing high dimensional single CTC profiling, providing early insight into CTC heterogeneity and allowing comparisons to breast cancer cell lines widely used for drug discovery. Methodology/Principal Findings We purified CTCs using the MagSweeper, an immunomagnetic enrichment device that isolates live tumor cells from unfractionated blood. CTCs that met stringent criteria for further analysis were obtained from 70% (14/20) of primary and 70% (21/30) of metastatic breast cancer patients; none were captured from patients with non-epithelial cancer (n = 20) or healthy subjects (n = 25). Microfluidic-based single cell transcriptional profiling of 87 cancer-associated and reference genes showed heterogeneity among individual CTCs, separating them into two major subgroups, based on 31 highly expressed genes. In contrast, single cells from seven breast cancer cell lines were tightly clustered together by sample ID and ER status. CTC profiles were distinct from those of cancer cell lines, questioning the suitability of such lines for drug discovery efforts for late stage cancer therapy. Conclusions/Significance For the first time, we directly measured high dimensional gene expression in individual CTCs without the common practice of pooling such cells. Elevated transcript levels of genes associated with metastasis NPTN, S100A4, S100A9, and with epithelial mesenchymal transition: VIM, TGFß1, ZEB2, FOXC1, CXCR4, were striking compared to cell lines. Our findings demonstrate that profiling CTCs on a cell-by-cell basis is possible and may facilitate the application of ‘liquid biopsies’ to better model drug discovery.

[1]  Larry Norton,et al.  Tumor Self-Seeding by Circulating Cancer Cells , 2009, Cell.

[2]  David Padua,et al.  Roles of TGFβ in metastasis , 2009, Cell Research.

[3]  D. Mavroudis,et al.  Micrometastatic disease in breast cancer: clinical implications. , 2008, European journal of cancer.

[4]  T. Fehm,et al.  Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status , 2007, Breast Cancer Research.

[5]  Ramesh Ramakrishnan,et al.  High Throughput Gene Expression Measurement with Real Time PCR in a Microfluidic Dynamic Array , 2008, PloS one.

[6]  M. Barcellos-Hoff,et al.  Transforming growth factor-β in breast cancer: too much, too late , 2009, Breast Cancer Research.

[7]  G. Sauter,et al.  Changes in Cytoskeletal Protein Composition Indicative of an Epithelial-Mesenchymal Transition in Human Micrometastatic and Primary Breast Carcinoma Cells , 2005, Clinical Cancer Research.

[8]  Stefanie S Jeffrey,et al.  A molecular 'signature' of primary breast cancer cultures; patterns resembling tumor tissue , 2004, BMC Genomics.

[9]  T. Fehm,et al.  HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial , 2010, Breast Cancer Research and Treatment.

[10]  D. Mavroudis,et al.  Gene expression profile of circulating tumor cells in breast cancer by RT-qPCR , 2011, BMC Cancer.

[11]  Kjetil Boye,et al.  S100A4 and metastasis: a small actor playing many roles. , 2010, The American journal of pathology.

[12]  H. Lenz,et al.  EGFR Signaling and Drug Discovery , 2010, Oncology.

[13]  J. Engelman,et al.  The PI3K pathway as drug target in human cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  L. Kiesel,et al.  HER2-Positive Circulating Tumor Cells Indicate Poor Clinical Outcome in Stage I to III Breast Cancer Patients , 2006, Clinical Cancer Research.

[15]  W. El-Deiry,et al.  Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases , 2011, Oncotarget.

[16]  S. Badve,et al.  NF-κB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2 , 2007, Oncogene.

[17]  K. Pienta,et al.  Global gene expression profiling of circulating tumor cells. , 2005, Cancer research.

[18]  John A. Foekens,et al.  Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR , 2009, Breast Cancer Research and Treatment.

[19]  Mark M Davis,et al.  Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device , 2009, Proceedings of the National Academy of Sciences.

[20]  Jonathan W. Uhr,et al.  Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases , 2004, Clinical Cancer Research.

[21]  L. Ylagan,et al.  Isolation and Molecular Profiling of Bone Marrow Micrometastases Identifies TWIST1 as a Marker of Early Tumor Relapse in Breast Cancer Patients , 2007, Clinical Cancer Research.

[22]  R. Ratan,et al.  The Epidermal Growth Factor Receptor Engages Receptor Interacting Protein and Nuclear Factor-κB (NF-κB)-inducing Kinase to Activate NF-κB , 2001, The Journal of Biological Chemistry.

[23]  F. Marshall,et al.  Progressive epithelial to mesenchymal transitions in ARCaPE prostate cancer cells during xenograft tumor formation and metastasis , 2010, The Prostate.

[24]  N. Tonks,et al.  Protein tyrosine phosphatases: a diverse family of intracellular and transmembrane enzymes. , 1991, Science.

[25]  Jun Liu,et al.  Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  A. Hackett,et al.  MONOCLONAL MARKER THAT PREDICTS EARLY RECURRENCE OF BREAST CANCER , 1987, The Lancet.

[27]  C. Punt,et al.  Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  J. Thiery Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.

[29]  Caroline Dive,et al.  Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Yasuhiro Ito,et al.  S100A8 and S100A9 overexpression is associated with poor pathological parameters in invasive ductal carcinoma of the breast. , 2008, Current cancer drug targets.

[31]  E. Gundelfinger,et al.  Identification of novel tumor antigens with patient-derived immune-selected antibodies , 2009, Cancer Immunology, Immunotherapy.

[32]  Vlad Popovici,et al.  Selecting control genes for RT-QPCR using public microarray data , 2009, BMC Bioinformatics.

[33]  J. Barrett,et al.  PIK3CA Mutations May Be Discordant between Primary and Corresponding Metastatic Disease in Breast Cancer , 2010, Clinical Cancer Research.

[34]  Raghu Kalluri,et al.  The basics of epithelial-mesenchymal transition. , 2009, The Journal of clinical investigation.

[35]  Ronald W. Davis,et al.  Distinctive Responsiveness to Stromal Signaling Accompanies Histologic Grade Programming of Cancer Cells , 2011, PloS one.

[36]  Larry Norton,et al.  Clinical implications of cancer self-seeding , 2011, Nature Reviews Clinical Oncology.

[37]  J. Carethers,et al.  TGF-beta mediates PTEN suppression and cell motility through calcium-dependent PKC-alpha activation in pancreatic cancer cells. , 2008, American journal of physiology. Gastrointestinal and liver physiology.

[38]  Tanja Fehm,et al.  Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients , 2009, Breast Cancer Research.

[39]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.

[40]  I. Fabregat,et al.  Role of CXCR4/SDF-1 alpha in the migratory phenotype of hepatoma cells that have undergone epithelial-mesenchymal transition in response to the transforming growth factor-beta. , 2009, Cellular signalling.

[41]  Jaap M J den Toonder,et al.  Circulating tumor cell isolation and diagnostics: toward routine clinical use. , 2011, Cancer research.

[42]  S. Jeffrey,et al.  Basal carcinoma of the breast revisited: an old entity with new interpretations , 2008, Journal of Clinical Pathology.

[43]  S. Jeffrey,et al.  Genomics-based prognosis and therapeutic prediction in breast cancer. , 2005, Journal of the National Comprehensive Cancer Network : JNCCN.

[44]  J. Carethers,et al.  RAS/ERK modulates TGFbeta-regulated PTEN expression in human pancreatic adenocarcinoma cells. , 2007, Carcinogenesis.

[45]  Julian Parkhill,et al.  Single-cell genomics , 2008, Nature Reviews Microbiology.

[46]  A. Lluch,et al.  Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. , 2010, Cancer treatment reviews.

[47]  S. Digumarthy,et al.  Isolation of rare circulating tumour cells in cancer patients by microchip technology , 2007, Nature.

[48]  R. F. Harvey,et al.  A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY , 1980, The Lancet.

[49]  Ruud H. Brakenhoff,et al.  Detection, clinical relevance and specific biological properties of disseminating tumour cells , 2008, Nature Reviews Cancer.

[50]  R. Weinberg,et al.  Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits , 2009, Nature Reviews Cancer.

[51]  Sanjay Shete,et al.  uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues , 2006, Proceedings of the National Academy of Sciences.

[52]  S. Bodovitz,et al.  Single cell analysis: the new frontier in 'omics'. , 2010, Trends in biotechnology.

[53]  Stephen R Quake,et al.  Solving the "world-to-chip" interface problem with a microfluidic matrix. , 2003, Analytical chemistry.

[54]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[55]  S. Jeffrey,et al.  Circulating tumour cells demonstrate an altered response to hypoxia and an aggressive phenotype , 2010, British Journal of Cancer.

[56]  S. Jeffrey,et al.  Oxidative stress pathways highlighted in tumor cell immortalization: association with breast cancer outcome , 2007, Oncogene.

[57]  N. Tonks,et al.  The leukocyte common antigen (CD45): a putative receptor-linked protein tyrosine phosphatase. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[58]  Annibale Biggeri,et al.  Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients , 2009, Breast Cancer Research and Treatment.

[59]  W. J. Allard,et al.  Circulating tumor cells predict survival in patients with metastatic prostate cancer. , 2005, Urology.

[60]  W. Gerald,et al.  Identifying site-specific metastasis genes and functions. , 2005, Cold Spring Harbor symposia on quantitative biology.

[61]  R. Ratan,et al.  The epidermal growth factor receptor engages receptor interacting protein and nuclear factor-kappa B (NF-kappa B)-inducing kinase to activate NF-kappa B. Identification of a novel receptor-tyrosine kinase signalosome. , 2001, The Journal of biological chemistry.

[62]  C. Loehberg,et al.  Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. , 2011, Gynecologic oncology.

[63]  G. Hortobagyi,et al.  Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[64]  H. Feiler,et al.  Immutable functional attributes of histologic grade revealed by context-independent gene expression in primary breast cancer cells. , 2009, Cancer research.